Zotepine: a clinical review

Bibliography

• Petit M, Raniwalla J, Tweed J, et al. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 1996;32(1):81-7
   PubMed Web of Science ®Google Scholar
• Yang SY, Kao Yang YH, Chong MY, et al. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol Ther 2007;81(4):586-94
   PubMed Web of Science ®Google Scholar
• Palmgren K, Wighton A, Reynolds CW, et al. The safety and efficacy of zotepine in the treatment of schizophrenia: results of a one year naturalistic clinical trial. Int J Psychiatry Clin Practice 2000;4:299-306
   PubMed Web of Science ®Google Scholar
• Amann B, Sterr A, Mergl R, et al. Zotepine loading in acute and severely manic patients: a pilot study. Bipolar Disorders 2005;7(5):471-6
   PubMed Web of Science ®Google Scholar
• Young RC, Biggs JT, Ziegler VE, Meyer SA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35
   PubMed Web of Science ®Google Scholar
• Cummings JL. The neuropsychiatric inventory: assessing psychopathology in patients with dementia. Neurology 1997;48:S10-6
   PubMed Web of Science ®Google Scholar
• Koss E, Weiner M, Ernesto C, et al. Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study.Alzheimer Dis Assoc Disorder 1997;11(Suppl 2):S45-50
   Google Scholar
• Rainer Michael KM, Mucke Hermann AM, Kruger-Rainer, et al. Zotepine for behavioural and psychological symptoms in dementia: an open-label study. CNS Drugs 2004;18(1):49-55
   PubMed Web of Science ®Google Scholar
• Bonelli Raphael MN, Gerald L, et al. Zotepine in Huntington's disease. Hum Psychopharmacol 2003;18(3):227-9
   PubMed Web of Science ®Google Scholar
• Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999;368(2-3):277-83
   PubMed Web of Science ®Google Scholar
• Rowley H, Kilpatrick IC, Needham PL, Heal DJ. Elevation of extracellular cortical noradrenaline may contribute to the antidepressant activity of zotepine: an in vivo microdialysis study in freely moving rats. Neuropharmacology 1998;37(7):937-44
   PubMed Web of Science ®Google Scholar
• Shiraga T, Kaneko H, Iwasaki K, et al. Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica 1999;29(3):217-29
   PubMed Web of Science ®Google Scholar
• Tanaka O. Pharmacokinetics of zotepine and various factors affecting that of zotepine. Nihon Shinkei Seishin Yakurigaku Zasshi 1996;16(2):49-52
   PubMedGoogle Scholar
• Overall JE, Gorham DR. Introduction – The Brief Psychiatric Rating Scale (BPRS). Recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-9
   Web of Science ®Google Scholar
• Andreasen NC. The Scale for the Assessment of Negative symptoms (SANS): Conceptual and theoretical foundation. Br J Psychiatry 1989;155(Suppl 7):49-58
   Google Scholar
• Simpson GM, Angus JSW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45(Suppl):11-19
   Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology, revised ed. Washington, DC, US Department of Health, Education, and Welfare, 1976
   Google Scholar
• Cooper SJ, Butler A, Tweed J, et al. Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology 2000;150(3):237-43
   PubMed Web of Science ®Google Scholar
• Hwang T, Lin SK, Lin HN. Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol. J Formos Med Assoc 2001;100(12):811-6
   PubMed Web of Science ®Google Scholar
• Cooper SJ, Tweed J, Raniwalla J, et al. placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatrica Scandinavica 2000;101(3):218-25
   PubMed Web of Science ®Google Scholar
• Briken P, Nika E, Moritz S, et al. Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients. Schizophrenia Research. 2002;57:311-313
   Google Scholar
• Harada T, Otsuki S, Sato M, et al. Effectivity of zotepine in refractory psychoses: possible relationships between zotepine and non-dopamine psychosis. Pharmacopsychiatry 1987;20:47-51
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Sudo T, Hirano M, et al. Efficacy and safety of zotepine for patients with treatment-resistant schizophrenia. Schizophr Res 2006;87(1-3):332-3
   PubMed Web of Science ®Google Scholar
• Moller HJ, Riedel M, Muller N, et al. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. Pharmacopsychiatry 2004;37(6):270-8
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A, Gruppe H, Bauer U, et al. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 1997;30(2):35-42
   PubMed Web of Science ®Google Scholar
• Barnas C, Stuppack CH, Miler C, et al. Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol. Int Clin Psychopharmacol 1992;7:23-27
   PubMed Web of Science ®Google Scholar
• Dieterle DM, Albus MI, Eben E, et al. Preliminary experiences and results with the Munich version of the Andreasen scale. Pharmacopsychiatry 1991;19:96-100
   Google Scholar
• Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64(7):701-23
   PubMed Web of Science ®Google Scholar
• Taylor DM, McAskill R. Atypical antipsychotics and weight gain – a systematic review. Acta Psychiatrica Scandinavica 2000;101(6):416-32
   PubMed Web of Science ®Google Scholar
• Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001;24(1):59-73
   PubMed Web of Science ®Google Scholar
• Mackin Paul. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 2008;23(Suppl 1):3-14
   PubMed Web of Science ®Google Scholar
• Svestka J, Synek O, Tomanova J, et al. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-lab el trial in female in-patients. Neuroendocrinol Lett 2007;28(6):881-8
   PubMed Web of Science ®Google Scholar
• Kubota T, Ishikura T, Jibiki I. Three cases of alopecia areata induced by zotepine. Acta Neurologica 1993;15(3):200-3
   PubMedGoogle Scholar
• Chen KAO, Yang Yen Kuang, Chen Po See, et al. Two case studies of hypothermia induced by an increased dosage of zotepine in a combination therapy. Psychiatry Clin Neurosci 2003;57(4):369-71
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare Products Regulatory Agency (UK) Drug Analysis Print- Zotepine. Accessed September 2008. Available from: http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/YellowCarddata/Druganalysisprints/index.htm?indexChar=Z
   Google Scholar
• Kondo T, Tanaka O, Otani K, et al. Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug. Psychopharmacology 1996;1274:311-4
   PubMed Web of Science ®Google Scholar
• DeSilva P, Fenton M, Rathbone J. Zotepine for schizophrenia. [update of Cochrane Database Syst Rev 2000;(2):CD001948; PMID: 10796671]. Cochrane Database Syst Rev 2006;4:CD001948
   PubMedGoogle Scholar